Structures by: Lemmerer A.
Total: 351
<i>N</i>'-Cyclopentylidenepyridine-4-carbohydrazide
C11H13N3O
Acta Crystallographica Section E (2012) 68, 5 o1299
a=15.762(3)Å b=8.1144(16)Å c=16.015(3)Å
α=90° β=90° γ=90°
6-Aminonicotinamide
C6H7N3O
Acta Crystallographica Section E (2012) 68, 8 o2449
a=14.3483(6)Å b=4.8143(2)Å c=9.6685(4)Å
α=90° β=99.215(2)° γ=90°
(+-)-(<i>rel</i>-3<i>R</i>,3'<i>R</i>)-1,1'-Dimethyl-3,3'-bipyrrolidine-2,2'- dithione
C10H16N2S2
Acta Crystallographica Section E (2012) 68, 11 o3211
a=20.520(3)Å b=5.7237(7)Å c=11.220(2)Å
α=90° β=122.009(5)° γ=90°
2,3-Dihydro-1<i>H</i>-pyrrolo[1,2-<i>a</i>]indole-9-carbonitrile
C12H10N2
Acta Crystallographica Section E (2012) 68, 12 o3306
a=9.1383(3)Å b=9.5340(3)Å c=12.3138(4)Å
α=90.794(2)° β=90.528(2)° γ=116.272(2)°
(2<i>E</i>)-1-Phenyl-2-[1-(2-phenylprop-2-en-1-yl)pyrrolidin-2-ylidene]ethanone
C21H21NO
Acta Crystallographica Section E (2012) 68, 12 o3281
a=5.7806(6)Å b=7.9407(7)Å c=9.6089(9)Å
α=82.579(7)° β=76.793(7)° γ=83.510(7)°
4-Aminopyridinium 2-chloro-4-nitrobenzoate monohydrate
C5H7N2,C7H3ClNO4,H2O
Acta Crystallographica Section E (2012) 68, 12 o3361
a=14.4500(5)Å b=14.3300(5)Å c=6.9918(2)Å
α=90° β=97.804(2)° γ=90°
(N'-(diphenylmethylene)isonicotinohydrazide)_(salicylic acid)
C19H15N3O,C7H6O3
Crystal Growth & Design (2015) 15, 8 3813
a=25.8071(6)Å b=6.9240(2)Å c=12.2426(3)Å
α=90° β=103.5010(10)° γ=90°
(N'-(bis(2-hydroxyphenyl)methylene)isonicotinohydrazide)_(salicyclic acid)
C19H15N3O3,C7H6O3
Crystal Growth & Design (2015) 15, 8 3813
a=25.010(2)Å b=6.9708(7)Å c=12.4779(11)Å
α=90° β=90.949(6)° γ=90°
(N'-(di-p-tolylmethylene)isonicotinohydrazide)_(salicyclic acid) Form I
C21H19N3O,C7H6O3
Crystal Growth & Design (2015) 15, 8 3813
a=9.9062(2)Å b=12.0906(3)Å c=12.4633(3)Å
α=113.5360(10)° β=113.0770(10)° γ=96.2970(10)°
(N'-(di-p-tolylmethylene)isonicotinohydrazide)_(salicylic acid) Form II
C21H19N3O,C7H6O3
Crystal Growth & Design (2015) 15, 8 3813
a=8.2520(3)Å b=11.2852(4)Å c=12.9411(5)Å
α=77.516(2)° β=85.880(2)° γ=82.910(2)°
((E)-N'-((4-(dimethylamino)phenyl)(phenyl)methylene)isonicotinohydrazide)_ (salicylic acid)
C21H20N4O,C7H6O3
Crystal Growth & Design (2015) 15, 8 3813
a=7.0057(4)Å b=11.5495(7)Å c=15.6046(9)Å
α=87.598(4)° β=82.792(4)° γ=72.850(3)°
((R)-1-phenylethylammonium)2\τimes (naphthalene-1,5-disulfonate)
2(C8H12N),C10H6O6S2
Crystal Growth & Design (2009) 9, 5 2265
a=10.689(2)Å b=11.221(2)Å c=21.392(4)Å
α=90° β=93.74(3)° γ=90°
(isonicotinamide).(diclofenac)
C14H11Cl2NO2,C6H6N2O
Crystal Growth & Design (2011) 11, 1 75
a=7.4641(3)Å b=8.8223(2)Å c=14.8006(6)Å
α=89.144(2)° β=87.628(2)° γ=82.788(2)°
(isonicotinamide).(nicotinamide)
C6H6N2O
Crystal Growth & Design (2011) 11, 1 75
a=7.9828(4)Å b=10.9899(8)Å c=14.7699(11)Å
α=68.585(3)° β=87.300(4)° γ=79.219(4)°
(isonicotinamide).(clofibric acid)
C10H11ClO3,C6H6N2O
Crystal Growth & Design (2011) 11, 1 75
a=6.9843(2)Å b=15.8948(5)Å c=16.2722(5)Å
α=110.079(2)° β=99.792(2)° γ=95.324(2)°
(isonicotinamide) hydrate Form I
C6H6N2O,H2O
Crystal Growth & Design (2011) 11, 1 75
a=7.418(2)Å b=10.774(3)Å c=16.608(5)Å
α=90° β=92.686(7)° γ=90°
(isonicotinamide) hydrate Form II
C6H6N2O,H2O
Crystal Growth & Design (2011) 11, 1 75
a=19.0991(17)Å b=7.4858(7)Å c=22.7304(15)Å
α=90° β=123.792(5)° γ=90°
Bis(cyclopropylammonium).(terephthalate)
C8H4O4,2(C3H8N)
Crystal Growth & Design (2011) 11, 2 583
a=10.036(5)Å b=19.177(10)Å c=7.628(4)Å
α=90° β=100.228(12)° γ=90°
Bis(cyclobutylammonium).(terephthalate).(H2O)
C8H4O4,2(C4H10N),H2O
Crystal Growth & Design (2011) 11, 2 583
a=7.484(2)Å b=11.332(4)Å c=11.999(4)Å
α=104.202(6)° β=101.783(7)° γ=106.211(7)°
Bis(cyclopentylammonium).(terephthalate)
C5H12N,0.5(C8H4O4)
Crystal Growth & Design (2011) 11, 2 583
a=10.2924(16)Å b=6.3171(10)Å c=14.574(2)Å
α=90° β=106.009(11)° γ=90°
Bis(cycloheptylammonium).(terephthalate)
C7H16N,0.5(C8H4O4)
Crystal Growth & Design (2011) 11, 2 583
a=11.1210(10)Å b=6.2292(5)Å c=16.3020(14)Å
α=90° β=102.800(4)° γ=90°
Bis(cyclooctylammonium).(terephthalate)
C8H18N,0.5(C8H4O4)
Crystal Growth & Design (2011) 11, 2 583
a=6.5205(9)Å b=9.0147(13)Å c=11.2738(18)Å
α=67.047(8)° β=74.083(8)° γ=79.039(8)°
Bis(cyclododecylammonium).(terephthalate)
C12H26N,0.5(C8H4O4)
Crystal Growth & Design (2011) 11, 2 583
a=5.44720(10)Å b=8.6949(2)Å c=16.5626(5)Å
α=94.434(2)° β=93.198(2)° γ=97.7750(10)°
(4-hydroxybenzoic acid).(nicotinamide)
C7H6O3,C6H6N2O
Crystal Growth & Design (2011) 11, 5 2011
a=30.962(4)Å b=7.3707(10)Å c=11.2227(15)Å
α=90° β=107.777(6)° γ=90°
(m-hydroxybenzoic acid).bis(triphenylphosphine)
2(C18H15OP),C7H6O3
Crystal Growth & Design (2011) 11, 5 2011
a=11.6000(10)Å b=13.5690(12)Å c=23.303(2)Å
α=90° β=90.567(2)° γ=90°
((RS)-mandelic acid).(acridine)
C13H9N,C8H8O3
Crystal Growth & Design (2011) 11, 5 2011
a=10.320(3)Å b=21.133(7)Å c=7.825(3)Å
α=90° β=102.105(6)° γ=90°
2-[4-[2-(4-chlorobenzamide)ethyl]phenoxy]-2-methylpropanoic acid
C19H20ClNO4
Crystal Growth & Design (2009) 9, 6 2646
a=10.3118(4)Å b=17.6601(14)Å c=19.7133(16)Å
α=90° β=90° γ=90°
2-[4-[2-(4-chlorobezamide)ethyl]phenoxy]-2-methylpropanoic acid
C19H20ClNO4
Crystal Growth & Design (2009) 9, 6 2646
a=10.7849(5)Å b=15.7886(7)Å c=11.4932(5)Å
α=90° β=115.875(2)° γ=90°
(3-hydroxybenzoic acid).(acridine) form I
C13H9N,C7H6O3
Crystal Growth & Design (2013) 13, 9 3935
a=6.8072(14)Å b=9.4831(19)Å c=24.016(5)Å
α=90° β=94.459(4)° γ=90°
(3-hydroxybenzoic acid).bis(acridine)
2(C13H9N),C7H6O3
Crystal Growth & Design (2013) 13, 9 3935
a=10.222(3)Å b=11.687(3)Å c=11.903(3)Å
α=110.667(5)° β=99.266(6)° γ=100.742(6)°
(3-hydroxybenzoic acid).(acridine) Form II
C13H9N,C7H6O3
Crystal Growth & Design (2013) 13, 9 3935
a=7.0913(18)Å b=9.287(2)Å c=12.972(3)Å
α=72.937(5)° β=75.915(5)° γ=80.609(5)°
(2,4-dihydroxybenzoic acid).(nicotinamide) methanol solvate
C7H6O4,C6H6N2O,CH4O
Crystal Growth & Design (2013) 13, 9 3935
a=7.042(6)Å b=7.280(6)Å c=14.536(11)Å
α=77.364(15)° β=80.549(17)° γ=65.514(15)°
(2,4-dihydroxybenzoic acid).(nicotinamide) Form II
C7H6O4,C6H6N2O
Crystal Growth & Design (2013) 13, 9 3935
a=12.464(3)Å b=8.2856(16)Å c=12.665(3)Å
α=90° β=109.579(5)° γ=90°
(2,4-dihydroxybenzoic acid).(nicotinamide) Form I
C7H6O4,C6H6N2O1
Crystal Growth & Design (2013) 13, 9 3935
a=5.8411(9)Å b=8.1695(14)Å c=13.4181(19)Å
α=96.617(5)° β=91.353(4)° γ=94.753(7)°
(malonic acid).bis(nicotinamide) Form I
2(C6H6N2O),C3H4O4
Crystal Growth & Design (2013) 13, 9 3935
a=32.783(3)Å b=4.0815(3)Å c=12.4392(7)Å
α=90° β=90° γ=90°
(nicotinamide).(pimelic acid) Form II
C7H12O4,C6H6N2O
Crystal Growth & Design (2013) 13, 9 3935
a=8.838(3)Å b=31.514(8)Å c=5.252(2)Å
α=90° β=90° γ=90°
Bis(heptylammonium)tetraiodoplumbate(ii) PHASE III
2(C7H18N),I4Pb
Dalton transactions (Cambridge, England : 2003) (2012) 41, 4 1146-1157
a=9.0126(2)Å b=8.7087(2)Å c=34.5612(10)Å
α=90° β=90° γ=90°
Bis(octylammonium)tetraiodoplumbate(ii) PHASE II
2(C8H20N),I4Pb
Dalton transactions (Cambridge, England : 2003) (2012) 41, 4 1146-1157
a=8.9817(4)Å b=8.6886(3)Å c=37.4821(18)Å
α=90° β=90° γ=90°
2(C8H12N),Cl4Zn
2(C8H12N),Cl4Zn
CrystEngComm (2011) 13, 10 3485
a=7.432(14)Å b=24.68(3)Å c=11.157(18)Å
α=90.00° β=91.70(14)° γ=90.00°
2(C8H12N),Br4Cd
2(C8H12N),Br4Cd
CrystEngComm (2011) 13, 10 3485
a=7.8680(9)Å b=25.864(3)Å c=11.0185(14)Å
α=90.00° β=91.086(2)° γ=90.00°
(4-hydroxybenzoic acid).(isonicotinic acid hydrazide)
C6H7N3O,C7H6O3
CrystEngComm (2010) 12, 10 2856
a=12.9083(5)Å b=4.98980(10)Å c=20.3294(9)Å
α=90° β=91.850(4)° γ=90°
(2,4-dihydroxybenzoic acid).(isonicotinic acid hydrazide)
C6H7N3O,C7H6O4
CrystEngComm (2010) 12, 10 2856
a=8.1931(4)Å b=5.0698(2)Å c=30.2815(13)Å
α=90° β=94.923(4)° γ=90°
Bis(3-iodopropylammonium)tetraiodoplumbate(ii)
I4Pb,2(C3H9IN)
CrystEngComm (2010) 12, 4 1290
a=14.0739(15)Å b=9.0379(10)Å c=8.4723(10)Å
α=90° β=99.246(5)° γ=90°
Bis(2-bromoethylammonium)tetraiodoplumbate(ii)
I4Pb,2(C2H7BrN)
CrystEngComm (2010) 12, 4 1290
a=12.8543(7)Å b=20.7714(13)Å c=6.4866(4)Å
α=90° β=90° γ=90°
Hexamethylenetetraminium hydrogen bis(2-chloro-4-nitro-benzoate)
C6H13N4,H(C7H3.50ClNO4)2
Acta crystallographica. Section E, Crystallographic communications (2017) 73, Pt 11 1630-1635
a=8.2777(2)Å b=19.7942(5)Å c=13.5331(4)Å
α=90° β=90° γ=90°
Cyclooctylaminium cinnamate
C8H18N,C9H7O2
Acta Crystallographica Section C (2012) 68, 5 o188-o194
a=24.4790(4)Å b=6.2800(4)Å c=22.6340(5)Å
α=90° β=114.894(2)° γ=90°
((E)-N'-(phenyl(p-tolyl)methylene)isonicotinohydrazide)_(salicyclic acid),
C20H17N3O,C7H6O3
Crystal Growth & Design (2015) 15, 8 3813
a=6.6193(2)Å b=12.3234(3)Å c=14.4180(3)Å
α=98.727(2)° β=98.596(2)° γ=100.665(2)°
(E)-N'-((4-aminophenyl)(phenyl)methylene)isonicotinohydrazide)_(salicylic acid)
C19H16N4O,C7H6O3
Crystal Growth & Design (2015) 15, 8 3813
a=9.2815(3)Å b=11.7198(3)Å c=12.2187(3)Å
α=94.4050(10)° β=110.971(2)° γ=113.076(2)°
(E)-N'-((4-aminophenyl)(phenyl)methylene)isonicotinohydrazide)_(salicylic acid)
C19H16N4O,C7H6O3
Crystal Growth & Design (2015) 15, 8 3813
a=7.8452(3)Å b=10.7034(4)Å c=13.1775(5)Å
α=90° β=93.234(3)° γ=90°
Bis(cyclohexylammonium)terepthalate with Disorder Model
2(C6H14N),C8H4O4
Crystal Growth & Design (2011) 11, 2 583
a=6.4126(2)Å b=8.3680(3)Å c=28.9437(8)Å
α=95.534(2)° β=90.510(2)° γ=96.869(2)°
(malonic acid).bis(nicotinamide) Form II
2(C6H6N2O),C3H4O4
Crystal Growth & Design (2013) 13, 9 3935
a=11.804(3)Å b=5.3360(13)Å c=25.121(6)Å
α=90° β=94.484(5)° γ=90°